This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human FOLR2 Protein, His Tag
catalog :
FO2-H5223
quantity :
100 ug, 1 mg
price :
230 USD, 1200 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
FO2-H5223
product name :
Human FOLR2 Protein, His Tag
quantity :
100 ug, 1 mg
price :
230 USD, 1200 USD
quantity & price :
$230/100ug,$1200/1mg (200ug × 5)
target :
FOLR2
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human FOLR2, His Tag (FO2-H5223) is expressed from human 293 cells (HEK293). It contains AA Thr 17 - His 228 (Accession # P14207-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human FOLR2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in Tris and Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Folate receptor beta is also known as Folate receptor 2, FBP, FOLR2, BETA-HFR, FBP/PL-1, FR-BETA, FR-P3, and is a member of the folate receptor (FOLR) family. and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. This protein has a 68% and 79% sequence homology with the FOLR1 and FOLR3 proteins, respectively. The FOLR2 protein was originally thought to exist only in placenta, but is also detected in spleen, bone marrow, and thymus. FOLR2 is predominantly expressed in placenta, cells of the neutrophilic lineage, and some CD34+ hematopoietic progenitor cells. It is upregulated on myeloid leukemias, head and neck squamous cell carcinomas, and several nonepithelial cancers. It is also upregulated on macrophages and monocytes at chronic inflammatory sites including rheumatoid arthritis synovium and glioblastoma. FOLR2 is a marker for macrophages generated in the presence of M-CSF, but not GM-CSF. Its expression correlates with increased folate uptake ability. Folate conjugates of therapeutic drugs are a potential immunotherapy tool to target tumor-associated macrophages.
References :
(1) Ratnam, M. et al., 1989, Biochemistry, 28(20):8249-54.
(2) Ross, J.F. et al., 1999, Cancer, 85:348.
(3) Reddy, J.A. et al., 1999, Blood, 93:3940.
(4) Ross, J.F. et al.,1994, Cancer 73:2432.
(5) van der Heijden, J.W. et al., 2009, Arthritis Rheum. 60:12.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments